secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001493152-23-032118
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908
--------------------------------------------------------------------------------

- Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.
- IND/CTA filing for GT-2108 expected by Q3 2024; development supported by $500k Crohn's & Colitis Foundation grant.
- Milestone payments (cash or stock at Palisade's election) and royalty payments on sales; Palisade to fund all costs after first IND/CTA approval.
- Second program GT-1908 targeting fibrostenotic Crohn's Disease via oral PDE4 compound.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/0001493152-23-032118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer